Nuformix plc
("Nuformix" or the "Company")
Nuformix Reports Results from Novel Pre-Clinical Trial in IPF for NXP002 Programme
Data show Nuformix Investigational Candidates (NXP002) outperform current standard of care
Multi-patient tissue studies were performed in partnership with
· Data demonstrates NXP002 candidates strongly inhibit fibrosis ex-vivo, even in very severely fibrotic patient tissue, giving strong support for treating IPF and other fibrotic lung conditions
· In addition, NXP002 demonstrated specific action measured against key inflammatory targets
· NXP002 out-performed current standard of care treatment, Esbriet ® (pirfenidone)
In partnership with the Newcastle University Fibrosis Research Group,
Dr Dan Gooding, CEO, Nuformix plc, said: "Despite the advent of new treatments, life expectancy has not really changed for patients diagnosed with IPF. Few patients respond to current treatments and have to tolerate severe side effects that dramatically impact quality of life - severe vomiting on one therapy or severe diarrhoea on the other. This promising data gives us confidence in our ability to both inhibit fibrosis and attenuate inflammation in patients without these side effects.
"
Nuformix will now seek to optimise delivery of a candidate within its NXP002 programme to maximise efficacy and tolerability using its patented novel drug forms before moving into patient studies.
Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the publication of this announcement via a Regulatory Information Service and accordingly, this inside information is now considered to be in the public domain.
Enquiries:
Nuformix plc Dr Dan Gooding, Chief Executive Officer |
+44 (0)1223 423667
|
Optimum Strategic Communications Supriya Mathur, Mary Clark Email: nuformix@optimumcomms.com |
+44 (0) 203 950 9144
|
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.
Nuformix has created an IP portfolio of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in
Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.
About Fibrosis
Fibrotic disease is typically associated with high patient mortality, increasing prevalence and a lack of safe and effective treatments. Whilst, fibrosis treatments are in their infancy the emerging lung fibrosis market demonstrates their blockbuster potential. Markets for other fibrotic conditions are under-developed, with large and growing patient populations (e.g. the global liver disease market is predicted to reach
Nuformix filed an additional patent in September 2018 relating to NXP002 products in order to capture a wider range of options in the treatment of fibrosis given its broad anti-fibrotic potential with relevance to unmet needs in multiple life-threatening conditions.
About the IPF Model
Ground-breaking research at
[1] (Pirfenidone, Esbriet ®), Esbriet (Pirfenidone, Roche) and OFEV (Nintedanib, BI) are the only approved treatments.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the